Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of amrubicin versus topotecan in previously treated small cell lung cancer
2007-003989-18Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Amrubicin with Topotecan (2 arms). Primary endpoint: Overall survival. Started Dec 2007; status: completed.
02
Drugs
amrubicintopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2007-003989-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003989-18.